Con: Focal Therapy for Prostate Cancer – Another Unnecessary Tool
Dr. Bagrodia explains why focal therapy for prostate cancer remains investigational, citing limited candidacy, unclear efficacy, and safety concerns.
Read More
Select Page
Aditya Bagrodia MD, FACS | Mar 2026
Dr. Bagrodia explains why focal therapy for prostate cancer remains investigational, citing limited candidacy, unclear efficacy, and safety concerns.
Read MoreJ. Michael Randall, MD | Mar 2026
Dr. Randall outlines evidence-based intensification with long-term ADT and selected use of abiraterone for very high-risk localized prostate cancer.
Read MoreRyan P. Terlecki, MD, FACS | Mar 2026
A practical algorithm to streamline evaluation and management of chronic scrotal pain while improving patient and provider experience.
Read MoreJennifer A. Miles-Thomas, MD, MBA, URPS | Mar 2026
This presentation explains how artificial intelligence affects healthcare workflows, clinician oversight, and operational decisions within urology.
Read MoreAmy M. Pearlman, MD | Mar 2026
How testosterone therapy may support muscle preservation and metabolic health beyond traditional replacement.
Read More